摘要
前列腺癌（PCa）是男性中最常见的癌症。 从局部PCa到抗阉割PCa（疾病的终末期）的演变通常与p53，雄激素受体，PTEN和ETS基因融合产物等基因的变化有关。 有证据表明二甲双胍（MET）和丙戊酸（VPA）在单独使用或与其他疗法联合使用时，可能会在减缓PCa进展方面发挥作用。 本综述概述了MET和VPA的应用，单独使用和与其他药物联合用于PCa治疗，将这些药物的反应与PCa中常见的分子变化相关联，然后描述了MET和VPA联合作用的可能性。 基于潜在的相互作用机制，对前列腺癌进行全身治疗。
关键词: 二甲双胍，丙戊酸，前列腺癌，化疗，mTOR，AMPK，雄激素信号通路，p53蛋白，PTEN，ETS基因融合，ERG过表达，组蛋白去乙酰化酶抑制剂。
图形摘要
[2]
Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet‐Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin., 2015, 65(2), 87-108.
[3]
Heidenreich, A.; Bastian, P.J.; Bellmunt, J.; Bolla, M.; Joniau, S.; van der Kwast, T.; Mason, M.; Matveev, V.; Wiegel, T.; Zattoni, F. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur. Urol., 2014, 65(1), 124-137.
[4]
Luo, Q.; Yu, X.Q.; Smith, D.P.; O’Connell, D.L. A population-based study of progression to metastatic prostate cancer in Australia. Cancer Epidemiol., 2015, 39(4), 617-622.
[5]
Hirst, C.; Cabrera, C.; Kirby, M. Epidemiology of castration resistant prostate cancer: A longitudinal analysis using a UK primary care database. Cancer Epidemiol., 2012, 36(6), e349-e353.
[6]
Ryan, C.J.; Smith, M.R.; Fizazi, K.; Saad, F.; Mulders, P.F.; Sternberg, C.N.; Miller, K.; Logothetis, C.J.; Shore, N.D.; Small, E.J. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol., 2015, 16(2), 152-160.
[7]
Beer, T.M.; Armstrong, A.J.; Rathkopf, D.E.; Loriot, Y.; Sternberg, C.N.; Higano, C.S.; Iversen, P.; Bhattacharya, S.; Carles, J.; Chowdhury, S. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med., 2014, 371(5), 424-433.
[8]
Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Théodore, C.; James, N.D.; Turesson, I. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 2004, 351(15), 1502-1512.
[9]
Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med., 2010, 363(5), 411-422.
[10]
De Bono, J.S.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J-P.; Kocak, I.; Gravis, G.; Bodrogi, I.; Mackenzie, M.J.; Shen, L. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet, 2010, 376(9747), 1147-1154.
[11]
Nilsson, S.; Franzén, L.; Parker, C.; Tyrrell, C.; Blom, R.; Tennvall, J.; Lennernäs, B.; Petersson, U.; Johannessen, D.C.; Sokal, M. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol., 2007, 8(7), 587-594.
[12]
Müller, H.; Reinwein, H. Zur Pharmakologie des Galegins. Naunyn-Schmiedebergs Archiv experiment. Pathol. Pharmakol, 1927, 125(3-4), 212-228.
[13]
Shaw, R.J.; Lamia, K.A.; Vasquez, D.; Koo, S-H.; Bardeesy, N.; DePinho, R.A.; Montminy, M.; Cantley, L.C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 2005, 310(5754), 1642-1646.
[14]
Kozka, I.; Clark, A.; Reckless, J.; Cushman, S.; Gould, G.; Holman, G. The effects of insulin on the level and activity of the GLUT4 present in human adipose cells. Diabetologia, 1995, 38(6), 661-666.
[15]
Burton, B. On the propyl derivatives and decomposition products of ethylacetoacetate. J. Am. Chem. Soc., 1882, 3, 385-395.
[16]
Meunier, H.; Carraz, G.; Neunier, Y.; Eymard, P.; Aimard, M. Pharmacodynamic properties of N-dipropylacetic acid. Therapie, 1962, 18, 435-438.
[17]
Chen, Y.; Pan, R.L.; Zhang, X.L.; Shao, J.Z.; Xiang, L.X.; Dong, X.J.; Zhang, G.R. Induction of hepatic differentiation of mouse bone marrow stromal stem cells by the histone deacetylase inhibitor VPA. J. Cell. Mol. Med., 2009, 13(8b), 2582-2592.
[18]
Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 2001, 108(8), 1167-1174.
[19]
Ben-Sahra, I.; Laurent, K.; Loubat, A.; Giorgetti-Peraldi, S.; Colosetti, P.; Auberger, P.; Tanti, J-F.; Le Marchand-Brustel, Y.; Bost, F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 2008, 27(25), 3576-3586.
[20]
Bolster, D.R.; Crozier, S.J.; Kimball, S.R.; Jefferson, L.S. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J. Biol. Chem., 2002, 277(27), 23977-23980.
[21]
Long, Y.C.; Zierath, J.R. AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Invest., 2006, 116(7), 1776-1783.
[22]
Bradbury, C.; Khanim, F.; Hayden, R.; Bunce, C.; White, D.; Drayson, M.; Craddock, C.; Turner, B. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia, 2005, 19(10), 1751-1759.
[23]
Rosato, R.R.; Almenara, J.A.; Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res., 2003, 63(13), 3637-3645.
[24]
Savickiene, J.; Borutinskaite, V-V.; Treigyte, G.; Magnusson, K-E.; Navakauskiene, R. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur. J. Pharmacol., 2006, 549(1), 9-18.
[25]
Martirosyan, A.; Leonard, S.; Shi, X.; Griffith, B.; Gannett, P.; Strobl, J. Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J. Pharmacol. Exp. Ther., 2006, 317(2), 546-552.
[26]
Rothermundt, C.; Hayoz, S.; Templeton, A.J.; Winterhalder, R.; Strebel, R.T.; Bärtschi, D.; Pollak, M.; Lui, L.; Endt, K.; Schiess, R. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur. Urol., 2014, 66(3), 468-474.
[27]
Azoulay, L.; Dell’Aniello, S.; Gagnon, B.; Pollak, M.; Suissa, S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol. Biomarkers Prev., 2011, 20(2), 337-344.
[28]
Joerger, M.; van Schaik, R.; Becker, M.; Hayoz, S.; Pollak, M.; Cathomas, R.; Winterhalder, R.; Gillessen, S.; Rothermundt, C. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis., 2015, 18(2), 167-172.
[29]
Fendt, S-M.; Bell, E.L.; Keibler, M.A.; Davidson, S.M.; Wirth, G.J.; Fiske, B.; Mayers, J.R.; Schwab, M.; Bellinger, G.; Csibi, A. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res., 2013, 73(14), 4429-4438.
[30]
Ben-Sahra, I.; Regazzetti, C.; Robert, G.; Laurent, K.; Le Marchand-Brustel, Y.; Auberger, P.; Tanti, J-F.; Giorgetti-Peraldi, S.; Bost, F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res., 2011, 71(13), 4366-4372.
[31]
Vecchio, S.; Giampreti, A.; Petrolini, V.; Lonati, D.; Protti, A.; Papa, P.; Rognoni, C.; Valli, A.; Rocchi, L.; Rolandi, L. Metformin accumulation: Lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. Clin. Toxicol., 2014, 52(2), 129-135.
[32]
Dowling, R.J.; Niraula, S.; Stambolic, V.; Goodwin, P.J. Metformin in cancer: translational challenges. J. Mol. Endocrinol., 2012, 48(3), R31-R43.
[33]
Carducci, M.A.; Gilbert, J.; Bowling, M.K.; Noe, D.; Eisenberger, M.A.; Sinibaldi, V.; Zabelina, Y.; Chen, T-I.; Grochow, L.B.; Donehower, R.C. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res., 2001, 7(10), 3047-3055.
[34]
Sandor, V.; Bakke, S.; Robey, R.W.; Kang, M.H.; Blagosklonny, M.V.; Bender, J.; Brooks, R.; Piekarz, R.L.; Tucker, E.; Figg, W.D. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res., 2002, 8(3), 718-728.
[35]
Kelly, W.K.; O’connor, O.A.; Krug, L.M.; Chiao, J.H.; Heaney, M.; Curley, T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J.P.; Schwartz, L. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol., 2005, 23(17), 3923-3931.
[36]
Shabbeer, S.; Kortenhorst, M.S.Q.; Kachhap, S.; Galloway, N.; Rodriguez, R.; Carducci, M.A. Multiple molecular pathways explain the anti‐proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate, 2007, 67(10), 1099-1110.
[37]
Sidana, A.; Wang, M.; Shabbeer, S.; Chowdhury, W.H.; Netto, G.; Lupold, S.E.; Carducci, M.; Rodriguez, R. Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. J. Biomed. Biotechnol., 2012, 2012, 180363.
[38]
Yang, H.; Hoshino, K.; Sanchez-Gonzalez, B.; Kantarjian, H.; Garcia-Manero, G. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk. Res., 2005, 29(7), 739-748.
[39]
Atmaca, A.; Al-Batran, S.E.; Maurer, A.; Neumann, A.; Heinzel, T.; Hentsch, B.; Schwarz, S.E.; Hovelmann, S.; Gottlicher, M.; Knuth, A.; Jager, E. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br. J. Cancer, 2007, 97(2), 177-182.
[40]
Friedmann, I.; Atmaca, A.; Chow, K.U.; Jager, E.; Weidmann, E. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J. Chemother., 2006, 18(4), 415-420.
[41]
Sharma, S.; Symanowski, J.; Wong, B.; Dino, P.; Manno, P.; Vogelzang, N. A phase II clinical trial of oral valproic acid in patients with castration-resistant prostate cancers using an intensive biomarker sampling strategy. Transl. Oncol., 2008, 1(3), 141.
[42]
Mahalingam, D.; Medina, E.C.; Esquivel, J.A.; Espitia, C.M.; Smith, S.; Oberheu, K.; Swords, R.; Kelly, K.R.; Mita, M.M.; Mita, A.C. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin. Cancer Res., 2010, 16(1), 141-153.
[43]
Vogelstein, B.; Papadopoulos, N.; Velculescu, V.E.; Zhou, S.; Diaz, L.A.; Kinzler, K.W. Cancer genome landscapes. Science, 2013, 339(6127), 1546-1558.
[44]
Gerlinger, M.; Rowan, A.J.; Horswell, S.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med., 2012, 2012(366), 883-892.
[45]
Dienstmann, R.; Jang, I.S.; Bot, B.; Friend, S.; Guinney, J. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov., 2015, 5(2), 118-123.
[46]
So, A.; Gleave, M.; Hurtado-Col, A.; Nelson, C. Mechanisms of the development of androgen independence in prostate cancer. World J. Urol., 2005, 23(1), 1-9.
[47]
Gravis, G.; Fizazi, K.; Joly, F.; Oudard, S.; Priou, F.; Esterni, B.; Latorzeff, I.; Delva, R.; Krakowski, I.; Laguerre, B. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol., 2013, 14(2), 149-158.
[48]
James, N.D.; Sydes, M.R.; Clarke, N.W.; Mason, M.D.; Dearnaley, D.P.; Spears, M.R.; Ritchie, A.W.; Parker, C.C.; Russell, J.M.; Attard, G. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, 2016, 387(10024), 1163-1177.
[49]
Colquhoun, A.; Venier, N.; Vandersluis, A.; Besla, R.; Sugar, L.; Kiss, A.; Fleshner, N.; Pollak, M.; Klotz, L.; Venkateswaran, V. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis., 2012, 15(4), 346-352.
[50]
Wang, Y.; Liu, G.; Tong, D.; Parmar, H.; Hasenmayer, D.; Yuan, W.; Zhang, D.; Jiang, J. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor. Prostate, 2015, 75(11), 1187-1196.
[51]
Chen-Pin, W.; Javier, H.; Lorenzo, C.; Downs, J.R.; Thompson, I.M.; Pollock, B.; Lehman, D. Statins and finasteride use differentially modify the impact of metformin on prostate cancer incidence in men with type 2 diabetes. Ann. Transl. Med. Epidemiol., 2014, 1(1), 1004.
[53]
Ben-Sahra, I.; Laurent, K.; Giuliano, S.; Larbret, F.; Ponzio, G.; Gounon, P.; Le Marchand-Brustel, Y.; Giorgetti-Peraldi, S.; Cormont, M.; Bertolotto, C. Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res., 2010, 70(6), 2465-2475.
[54]
Lehman, D.M.; Lorenzo, C.; Hernandez, J.; Wang, C.P. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care, 2012, 35(5), 1002-1007.
[55]
Danzig, M.R.; Kotamarti, S.; Ghandour, R.A.; Rothberg, M.B.; Dubow, B.P.; Benson, M.C.; Badani, K.K.; McKiernan, J.M. Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes. Prostate Cancer Prostatic Dis., 2015, 18(1), 63-68.
[56]
Babcook, M.A.; Shukla, S.; Fu, P.; Vazquez, E.J.; Puchowicz, M.A.; Molter, J.P.; Oak, C.Z.; MacLennan, G.T.; Flask, C.A.; Lindner, D.J. Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer. Mol. Cancer Ther., 2014, 13(10), 2288-2302.
[57]
Pennanen, P.; Syvala, H.; Blauer, M.; Savinainen, K.; Ylikomi, T.; Tammela, T.L.; Murtola, T.J. The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines. Eur. J. Pharmacol., 2016, 788, 160-167.
[58]
Saha, A.; Blando, J.; Tremmel, L.; DiGiovanni, J. Effect of metformin, rapamycin, and their combination on growth and progression of prostate tumors in HiMyc mice. Cancer Prev. Res., 2015, 8(7), 597-606.
[59]
Al-Hendy, A.; Diamond, M.P.; Boyer, T.G.; Halder, S.K. Vitamin D3 inhibits Wnt/β-catenin and mTOR signaling pathways in human uterine fibroid cells. J. Clin. Endocrinol. Metab., 2016, 101(4), 1542-1551.
[60]
Li, H.X.; Gao, J.M.; Liang, J.Q.; Xi, J.M.; Fu, M.; Wu, Y.J. Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway. Clin. Exp. Pharmacol. Physiol., 2015, 42(6), 711-717.
[61]
Cinatl, J., Jr; Cinatl, J.; Scholz, M.; Driever, P.H.; Henrich, D.; Kabickova, H.; Vogel, J-U.; Doerr, H.W.; Kornhuber, B. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs, 1996, 7(7), 766-773.
[62]
Ouyang, D-Y.; Ji, Y-H.; Saltis, M.; Xu, L-H.; Zhang, Y-T.; Zha, Q-B.; Cai, J-Y.; He, X-H. Valproic acid synergistically enhances the cytotoxicity of gossypol in DU145 prostate cancer cells: An iTRTAQ-based quantitative proteomic analysis. J. Proteomics, 2011, 74(10), 2180-2193.
[63]
Wissing, M.D.; Mendonca, J.; Kortenhorst, M.S.; Kaelber, N.S.; Gonzalez, M.; Kim, E.; Hammers, H.; van Diest, P.J.; Carducci, M.A.; Kachhap, S.K. Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. FASEB J., 2013, 27(10), 4279-4293.
[64]
Paller, C.J.; Wissing, M.D.; Mendonca, J.; Sharma, A.; Kim, E.; Kim, H.S.; Kortenhorst, M.S.; Gerber, S.; Rosen, M.; Shaikh, F.; Zahurak, M.L.; Rudek, M.A.; Hammers, H.; Rudin, C.M.; Carducci, M.A.; Kachhap, S.K. Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Med., 2014, 3(5), 1322-1335.
[65]
Qian, D.Z.; Wang, X.; Kachhap, S.K.; Kato, Y.; Wei, Y.; Zhang, L.; Atadja, P.; Pili, R. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res., 2004, 64(18), 6626-6634.
[66]
Wheler, J.J.; Janku, F.; Falchook, G.S.; Jackson, T.L.; Fu, S.; Naing, A.; Tsimberidou, A.M.; Moulder, S.L.; Hong, D.S.; Yang, H.; Piha-Paul, S.A.; Atkins, J.T.; Garcia-Manero, G.; Kurzrock, R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother. Pharmacol., 2014, 73(3), 495-501.
[67]
Wedel, S.; Hudak, L.; Seibel, J.M.; Juengel, E.; Oppermann, E.; Haferkamp, A.; Blaheta, R.A. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer. The Prostate, 2011, 71(7), 722-735.
[68]
Annicotte, J.S.; Iankova, I.; Miard, S.; Fritz, V.; Sarruf, D.; Abella, A.; Berthe, M.L.; Noel, D.; Pillon, A.; Iborra, F.; Dubus, P.; Maudelonde, T.; Culine, S.; Fajas, L. Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol. Cell. Biol., 2006, 26(20), 7561-7574.
[69]
Fortson, W.S.; Kayarthodi, S.; Fujimura, Y.; Xu, H.; Matthews, R.; Grizzle, W.E.; Rao, V.N.; Bhat, G.K.; Reddy, E.S.P. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int. J. Oncol., 2011, 39(1), 111.
[70]
David, K.A.; Mongan, N.P.; Smith, C.; Gudas, L.J.; Nanus, D.M. Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies. Cancer Biol. Ther., 2010, 9(9), 678-684.
[71]
Wedel, S.; Hudak, L.; Seibel, J.M.; Juengel, E.; Tsaur, I.; Wiesner, C.; Haferkamp, A.; Blaheta, R.A. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life sciences, 2011, 88(9-10), 418-424.
[72]
Zhang, X.; Zhang, X.; Huang, T.; Geng, J.; Liu, M.; Zheng, J. Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma. Int. J. Clin. Exp. Pathol., 2015, 8(3), 2823-2828.
[73]
Tran, L.N.; Kichenadasse, G.; Butler, L.M.; Centenera, M.M.; Morel, K.L.; Ormsby, R.J.; Michael, M.Z.; Lower, K.M.; Sykes, P.J. The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer. Mol. Cancer Ther., 2017, 16(12), 2689-2700.
[74]
Robinson, D.; Van Allen, E.M.; Wu, Y-M.; Schultz, N.; Lonigro, R.J.; Mosquera, J-M.; Montgomery, B.; Taplin, M-E.; Pritchard, C.C.; Attard, G. Integrative clinical genomics of advanced prostate cancer. Cell, 2015, 161(5), 1215-1228.
[75]
Taplin, M-E.; Bubley, G.J.; Shuster, T.D.; Frantz, M.E.; Spooner, A.E.; Ogata, G.K.; Keer, H.N.; Balk, S.P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 1995, 332(21), 1393-1398.
[76]
Feldman, B.J.; Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer, 2001, 1(1), 34-45.
[77]
Bookstein, R.; MacGrogan, D.; Hilsenbeck, S.G.; Sharkey, F.; Allred, D.C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res., 1993, 53(14), 3369-3373.
[78]
Zakikhani, M.; Dowling, R.; Fantus, I.G.; Sonenberg, N.; Pollak, M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res., 2006, 66(21), 10269-10273.
[79]
Gotlieb, W.H.; Saumet, J.; Beauchamp, M-C.; Gu, J.; Lau, S.; Pollak, M.N.; Bruchim, I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol. Oncol., 2008, 110(2), 246-250.
[80]
Okoshi, R.; Ozaki, T.; Yamamoto, H.; Ando, K.; Koida, N.; Ono, S.; Koda, T.; Kamijo, T.; Nakagawara, A.; Kizaki, H. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J. Biol. Chem., 2008, 283(7), 3979-3987.
[81]
Feng, Z.; Levine, A.J. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol., 2010, 20(7), 427-434.
[82]
Bensaad, K.; Vousden, K.H. p53: New roles in metabolism. Trends Cell Biol., 2007, 17(6), 286-291.
[83]
Chen, L.; Ahmad, N.; Liu, X. Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer. Cell Cycle, 2016, 15(6), 840-849.
[84]
Bode, A.M.; Dong, Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer, 2004, 4(10), 793-805.
[85]
Gu, W.; Roeder, R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 1997, 90(4), 595-606.
[86]
Feng, Z.; Hu, W.; De Stanchina, E.; Teresky, A.K.; Jin, S.; Lowe, S.; Levine, A.J. The regulation of AMPK β1, TSC2, and PTEN expression by p53: Stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res., 2007, 67(7), 3043-3053.
[87]
Hardie, D.G. Minireview: The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology, 2003, 144(12), 5179-5183.
[88]
Nicolini, C.; Ahn, Y.; Michalski, B.; Rho, J.M.; Fahnestock, M. Decreased mTOR signaling pathway in human idiopathic autism and in rats exposed to valproic acid. Acta Neuropathol. Commun., 2015, 3(1), 3.
[89]
Wedel, S.; Hudak, L.; Seibel, J.M.; Makarevic, J.; Juengel, E.; Tsaur, I.; Wiesner, C.; Haferkamp, A.; Blaheta, R.A. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin. Exp. Metastasis, 2011, 28(5), 479-491.
[90]
Chen, H.; Dzitoyeva, S.; Manev, H. Effect of valproic acid on mitochondrial epigenetics. Eur. J. Pharmacol., 2012, 690(1), 51-59.
[91]
Li, Y.; Chan, S.C.; Brand, L.J.; Hwang, T.H.; Silverstein, K.A.; Dehm, S.M. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res., 2013, 73(2), 483-489.
[92]
Tran, C.; Ouk, S.; Clegg, N.J.; Chen, Y.; Watson, P.A.; Arora, V.; Wongvipat, J.; Smith-Jones, P.M.; Yoo, D.; Kwon, A. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 2009, 324(5928), 787-790.
[93]
Xu, Y.; Chen, S-Y.; Ross, K.N.; Balk, S.P. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res., 2006, 66(15), 7783-7792.
[94]
Gaughan, L.; Logan, I.R.; Cook, S.; Neal, D.E.; Robson, C.N. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J. Biol. Chem., 2002, 277(29), 25904-25913.
[95]
Xia, Q.; Sung, J.; Chowdhury, W.; Chen, C-I.; Höti, N.; Shabbeer, S.; Carducci, M.; Rodriguez, R. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res., 2006, 66(14), 7237-7244.
[96]
Iacopino, F.; Urbano, R.; Graziani, G.; Muzi, A.; Navarra, P.; Sica, G. Valproic acid activity in androgen-sensitive and-insensitive human prostate cancer cells. Int. J. Oncol., 2008, 32(6), 1293-1303.
[97]
Chou, Y-W.; Chaturvedi, N.K.; Ouyang, S.; Lin, F-F.; Kaushik, D.; Wang, J.; Kim, I.; Lin, M-F. Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Lett., 2011, 311(2), 177-186.
[98]
Sobel, R.E.; Wang, Y.; Sadar, M.D. Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells. In Vitro Cell. Dev. Biol. Anim., 2006, 42(1-2), 33-39.
[99]
Kumari, S.; Schlanger, S.; Wang, D.; Liu, S.; Heemers, H. OR43-2:
defining co-regulator contribution to AR-dependent transcription
uncovers a novel AR-WDR77-p53-dependent transcriptional code. In Endocrine Society's 98th Annual Meeting and Expo, Endocrine
Society: Boston, 2016.
[100]
Tomlins, S.A.; Rhodes, D.R.; Perner, S.; Dhanasekaran, S.M.; Mehra, R.; Sun, X-W.; Varambally, S.; Cao, X.; Tchinda, J.; Kuefer, R.; Lee, C.; Montie, J.E.; Shah, R.B.; Pienta, K.J.; Rubin, M.A.; Chinnaiyan, A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 2005, 310(5748), 644-648.
[101]
Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S.I.; Puc, J.; Miliaresis, C.; Rodgers, L.; McCombie, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 1997, 275(5308), 1943-1947.
[102]
Attard, G.; Swennenhuis, J.F.; Olmos, D.; Reid, A.H.; Vickers, E.; A’Hern, R.; Levink, R.; Coumans, F.; Moreira, J.; Riisnaes, R. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res., 2009, 69(7), 2912-2918.
[103]
Bastola, D.R.; Pahwa, G.S.; Lin, M-F.; Cheng, P-W. Downregulation of PTEN/MMAC/TEP1 expression in human prostate cancer cell line DU145 by growth stimuli. Mol. Cell. Biochem., 2002, 236(1), 75-81.
[104]
Vazquez, F.; Ramaswamy, S.; Nakamura, N.; Sellers, W.R. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol., 2000, 20(14), 5010-5018.
[105]
Hara, S.; Oya, M.; Mizuno, R.; Horiguchi, A.; Marumo, K.; Murai, M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann. Oncol., 2005, 16(6), 928-933.
[106]
John, J.S.; Powell, K.; Conley-LaComb, M.K.; Chinni, S.R. TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression. J. Cancer Sci. Ther., 2012, 4(4), 94.
[107]
Rubin, M.A.; Maher, C.A.; Chinnaiyan, A.M. Common gene rearrangements in prostate cancer. J. Clin. Oncol., 2011, 29(27), 3659-3668.
[108]
Friedlander, T.W.; Roy, R.; Tomlins, S.A.; Ngo, V.T.; Kobayashi, Y.; Azameera, A.; Rubin, M.A.; Pienta, K.J.; Chinnaiyan, A.; Ittmann, M.M. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res., 2012, 72(3), 616-625.
[110]
Rahim, S.; Üren, A. Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer. Am. J. Transl. Res., 2013, 5(3), 254.
[111]
Tomlins, S.A.; Laxman, B.; Varambally, S.; Cao, X.; Yu, J.; Helgeson, B.E.; Cao, Q.; Prensner, J.R.; Rubin, M.A.; Shah, R.B. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (New York, NY), 2008, 10(2), 177.
[112]
Massoner, P.; Kugler, K.G.; Unterberger, K.; Kuner, R.; Mueller, L.A.; Fälth, M.; Schäfer, G.; Seifarth, C.; Ecker, S.; Verdorfer, I. Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y. PLoS One, 2013, 8(2), e55207.
[113]
Björkman, M.; Iljin, K.; Halonen, P.; Sara, H.; Kaivanto, E.; Nees, M.; Kallioniemi, O.P. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG‐positive prostate cancer. Int. J. Cancer, 2008, 123(12), 2774-2781.
[114]
Carver, B.S.; Tran, J.; Gopalan, A.; Chen, Z.; Shaikh, S.; Carracedo, A.; Alimonti, A.; Nardella, C.; Varmeh, S.; Scardino, P.T. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet., 2009, 41(5), 619-624.
[115]
Reid, A.; Attard, G.; Ambroisine, L.; Fisher, G.; Kovacs, G.; Brewer, D.; Clark, J.; Flohr, P.; Edwards, S.; Berney, D. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br. J. Cancer, 2010, 102(4), 678-684.
[116]
Bergheim, I.; Guo, L.; Davis, M.A.; Lambert, J.C.; Beier, J.I.; Duveau, I.; Luyendyk, J.P.; Roth, R.A.; Arteel, G.E. Metformin prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen activator inhibitor-1. Gastroenterology, 2006, 130(7), 2099-2112.
[117]
Van Beneden, K.; Geers, C.; Pauwels, M.; Mannaerts, I.; Verbeelen, D.; van Grunsven, L.A.; Van den Branden, C. Valproic acid attenuates proteinuria and kidney injury. J. Am. Soc. Nephrol., 2011, 22(10), 1863-1875.
[118]
El Sheikh, S.S.; Romanska, H.M.; Abel, P.; Domin, J.; Lalani, E-N. Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer-a pilot study. Neoplasia, 2008, 10(9), 949-953.
[119]
Taylor, B.S.; Schultz, N.; Hieronymus, H.; Gopalan, A.; Xiao, Y.; Carver, B.S.; Arora, V.K.; Kaushik, P.; Cerami, E.; Reva, B. Integrative genomic profiling of human prostate cancer. Cancer Cell, 2010, 18(1), 11-22.
[120]
Wu, X.; Senechal, K.; Neshat, M.S.; Whang, Y.E.; Sawyers, C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci., 1998, 95(26), 15587-15591.
[121]
Marcelli, M.; Ittmann, M.; Mariani, S.; Sutherland, R.; Nigam, R.; Murthy, L.; Zhao, Y.; DiConcini, D.; Puxeddu, E.; Esen, A. Androgen receptor mutations in prostate cancer. Cancer Res., 2000, 60(4), 944-949.
[122]
Currie, C.; Poole, C.; Gale, E. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia, 2009, 52(9), 1766-1777.
[123]
Nobes, J.P.; Langley, S.E.; Klopper, T.; Russell-Jones, D.; Laing, R.W. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int., 2012, 109(10), 1495-1502.
[124]
Monteagudo, S.; Perez-Martinez, F.C.; Perez-Carrion, M.D.; Guerra, J.; Merino, S.; Sanchez-Verdu, M.P.; Cena, V. Inhibition of p42 MAPK using a nonviral vector-delivered siRNA potentiates the anti-tumor effect of metformin in prostate cancer cells. Nanomedicine, 2012, 7(4), 493-506.
[125]
Babcook, M.A.; Sramkoski, R.M.; Fujioka, H.; Daneshgari, F.; Almasan, A.; Shukla, S.; Nanavaty, R.R.; Gupta, S. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells. Cell Death Dis., 2014, 5, e1536.
[126]
Bilen, M.A.; Lin, S.H.; Tang, D.G.; Parikh, K.; Lee, M.H.; Yeung, S.C.; Tu, S.M. Maintenance therapy containing metformin and/or zyflamend for advanced prostate cancer: A case series. Case Rep. Oncol. Med., 2015, 2015, 471861.
[127]
White-Al Habeeb, N.M.; Garcia, J.; Fleshner, N.; Bapat, B. Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells. Prostate, 2016, 76(16), 1507-1518.
[128]
Gonnissen, A.; Isebaert, S.; McKee, C.M.; Muschel, R.J.; Haustermans, K. The effect of metformin and GANT61 combinations on the radiosensitivity of prostate cancer cells. Int. J. Mol. Sci., 2017, 18(2), 399.
[129]
Mayer, M.J.; Klotz, L.H.; Venkateswaran, V. The Effect of metformin use during docetaxel chemotherapy on prostate cancer specific and overall survival of diabetic patients with castration resistant prostate cancer. J. Urol., 2017, 197(4), 1068-1075.
[130]
Gavrilov, V.; Leibovich, Y.; Ariad, S.; Lavrenkov, K.; Shany, S. A combined pretreatment of 1,25-dihydroxyvitamin D3 and sodium valproate enhances the damaging effect of ionizing radiation on prostate cancer cells. J. Steroid Biochem. Mol. Biol., 2010, 121(1-2), 391-394.
[131]
Wedel, S.; Hudak, L.; Seibel, J.M.; Makarevic, J.; Juengel, E.; Tsaur, I.; Waaga-Gasser, A.; Haferkamp, A.; Blaheta, R.A. Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the CDK-cyclin axis. BMC Cancer, 2011, 11, 375.
[132]
Hudak, L.; Tezeeh, P.; Wedel, S.; Makarevic, J.; Juengel, E.; Tsaur, I.; Bartsch, G.; Wiesner, C.; Haferkamp, A.; Blaheta, R.A. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion. Prostate, 2012, 72(16), 1719-1735.
[133]
Abrahamsson, P-A. Improving outcomes in prostate cancer: Time to tackle bone disorders. Eur. Urol. Suppl., 2009, 8(11), 821-822.
[134]
Xie, Z.; Dong, Y.; Scholz, R.; Neumann, D.; Zou, M-H. Phosphorylation of LKB1 at serine 428 by protein kinase C-ζ is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation, 2008, 117(7), 952-962.
[135]
Wheaton, W.W.; Weinberg, S.E.; Hamanaka, R.B.; Soberanes, S.; Sullivan, L.B.; Anso, E.; Glasauer, A.; Dufour, E.; Mutlu, G.M.; Budigner, G.S. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife, 2014, 3, e02242.
[136]
Shi, W.; Xiao, D.; Wang, L.; Dong, L.; Yan, Z.; Shen, Z.; Chen, S.; Chen, Y.; Zhao, W. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis., 2012, 3(3), e275.
[137]
Gwinn, D.M.; Shackelford, D.B.; Egan, D.F.; Mihaylova, M.M.; Mery, A.; Vasquez, D.S.; Turk, B.E.; Shaw, R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell, 2008, 30(2), 214-226.
[138]
Cerezo, M.; Tichet, M.; Abbe, P.; Ohanna, M.; Lehraiki, A.; Rouaud, F.; Allegra, M.; Giacchero, D.; Bahadoran, P.; Bertolotto, C. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol. Cancer Ther., 2013, 12(8), 1605-1615.
[140]
Jones, R.G.; Plas, D.R.; Kubek, S.; Buzzai, M.; Mu, J.; Xu, Y.; Birnbaum, M.J.; Thompson, C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell, 2005, 18(3), 283-293.
[141]
Xu, W.; Parmigiani, R.; Marks, P. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene, 2007, 26(37), 5541-5552.
[142]
Chipuk, J.E.; Kuwana, T.; Bouchier-Hayes, L.; Droin, N.M.; Newmeyer, D.D.; Schuler, M.; Green, D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science, 2004, 303(5660), 1010-1014.
[143]
Condorelli, F.; Gnemmi, I.; Vallario, A.; Genazzani, A.; Canonico, P. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br. J. Pharmacol., 2008, 153(4), 657-668.
[144]
Bennett, M.; Macdonald, K.; Chan, S-W.; Luzio, J.P.; Simari, R.; Weissberg, P. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis. Science, 1998, 282(5387), 290-293.
[145]
Waring, P.; Müllbacher, A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol. Cell Biol., 1999, 77(4), 312-317.
[146]
Müller, M.; Wilder, S.; Bannasch, D.; Israeli, D.; Lehlbach, K.; Li-Weber, M.; Friedman, S.L.; Galle, P.R.; Stremmel, W.; Oren, M. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med., 1998, 188(11), 2033-2045.
[147]
Owen-Schaub, L.B.; Zhang, W.; Cusack, J.C.; Angelo, L.S.; Santee, S.M.; Fujiwara, T.; Roth, J.A.; Deisseroth, A.B.; Zhang, W-W.; Kruzel, E. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol., 1995, 15(6), 3032-3040.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
Article Metrics
91
5